Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 124
- Registration Number
- NCT01619046
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Los Angeles Orthopaedic Hospital - Hemophilia Treatment Center, Los Angeles, California, United States
🇺🇸Harbor - UCLA Pediatrics, Torrance, California, United States
Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2014-01-03
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT01606163
- Locations
- 🇰🇷
Department of clinical pharmacology and therapeutics, Seoul, Korea, Republic of
To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 761
- Registration Number
- NCT01604239
- Locations
- 🇰🇷
Kyungpook national university hospital, Daegu, Kyungpook, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT01568580
Efficacy and Safety of Shinbaro Capsule
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 198
- Registration Number
- NCT01535417
Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2012-09-20
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT01524939
- Locations
- 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Kyung Hee university medical center, Seoul, Korea, Republic of
🇰🇷Kyung Hee university at Gangdong, Seoul, Korea, Republic of
Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
- Conditions
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT01406470
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Children's Hospital of Richmond, Richmond, Virginia, United States
🇺🇸AARA Research Center, Dallas, Texas, United States
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children
- Conditions
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 311
- Registration Number
- NCT01402713
- Locations
- 🇰🇷
The catholic university of Korea, Seoul st. mary's hospital, Banpo-dong, Seoul, Korea, Republic of
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 346
- Registration Number
- NCT01389466
- Locations
- 🇰🇷
Inha University Hospital, Inchon, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT01363934